london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal


Treatment of macular edema secondary to retinitis pigmentosa with intravitreal dexamethasone implant

Poster Details

First Author: S.Kadayifcilar TURKEY

Co Author(s):    B. Eldem                  0   0 0   0 0   0 0   0 0

Abstract Details


To evaluate the functional and anatomical results of intravitreal dexamethasone implant in cases with macular edema secondary to retinitis pigmentosa (RP).


Hacettepe University Medical School Department of Ophthalmology.


Data from six eyes of four patients receiving intravitreal dexamethasone implant for refractory macular edema secondary to RP were retrospectively evaluated. The best corrected visual acuity (BCVA) and central macular thickness (CMT) on spectral domain optical coherence tomography were assessed.


The mean age was 36 (range 17-42). The follow-up ranged between 4 and 18 months (mean 7,16 months). After intravitreal dexamethasone implantation all patients disclosed edema resolution for 4-7 months. Implant was repeated in two eyes at 6 months. BCVA changed from a mean of 39.67 letters (16-55) to a mean of 46.83 letters (25-60) and CMT changed from a mean of 573,33 microns (422-676) to a mean of 287 microns (180-334). No serious ocular or systemic adverse event was observed during the follow-up.


Intravitreal dexamethasone implant may be useful for 4-7 months in the treatment of refractory macular edema secondary to RP.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy